Verastem (VSTM) says it has completed the dose escalation portion of a Phase 1/ 1b trial of...


Verastem (VSTM) says it has completed the dose escalation portion of a Phase 1/ 1b trial of VS-6063 and paclitaxel in ovarian cancer patients. The anticipated Phase 2 dose of VS-6063 was reached "without any dose-limiting toxicities" and three out of six patients experienced a "significant" reduction in the marker that becomes elevated when the disease has progressed. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs